When do you discontinue PARP inhibitor maintenance after complete response to first line chemotherapy in a BRCA+ patient?
2 Answers
Mednet Member
Medical Oncology · Christie NHS Foundation Trust
I agree with Dr. @Dr. First Last that we have no data for PARPi maintenance beyond 2 years in the first line and would urge people to enroll in clinical trials which look at risks and benefits of longer maintenance, especially in patients harbouring a germline BRCA mutation.
With respect to all come...